These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 17688683)
1. Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum. Melichar B; Hyspler R; Dragounová E; Dvorák J; Kalábová H; Tichá A BMC Cancer; 2007 Aug; 7():155. PubMed ID: 17688683 [TBL] [Abstract][Full Text] [Related]
2. Intestinal permeability and vitamin A absorption in patients with chemotherapy-induced diarrhea. Melichar B; Dvorák J; Krcmová L; Hyspler R; Urbánek L; Solichová D Am J Clin Oncol; 2008 Dec; 31(6):580-4. PubMed ID: 19060591 [TBL] [Abstract][Full Text] [Related]
3. Intestinal permeability, vitamin A absorption and serum alpha-tocopherol during therapy with gefitinib. Melichar B; Dvorák J; Kalábová H; Hyspler R; Krcmová L; Kasparová M; Urbánek L; Solichová D Scand J Clin Lab Invest; 2010 Apr; 70(3):180-7. PubMed ID: 20205613 [TBL] [Abstract][Full Text] [Related]
4. Intestinal permeability in patients with chemotherapy-induced stomatitis. Melichar B; Kohout P; Brátová M; Solichová D; Králícková P; Zadák Z J Cancer Res Clin Oncol; 2001 May; 127(5):314-8. PubMed ID: 11355146 [TBL] [Abstract][Full Text] [Related]
5. Intestinal permeability in patients with metastatic colon cancer treated with patupilone. Melichar B; Hyšpler R; Tichá A; Kalábová H; Vitásková D; Zezulová M; Dvořák J; Cerman J; Doležel M Clin Chem Lab Med; 2014 Nov; 52(11):1649-55. PubMed ID: 24937505 [TBL] [Abstract][Full Text] [Related]
6. The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Keshavarzian A; Fields JZ; Vaeth J; Holmes EW Am J Gastroenterol; 1994 Dec; 89(12):2205-11. PubMed ID: 7977243 [TBL] [Abstract][Full Text] [Related]
7. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224 [TBL] [Abstract][Full Text] [Related]
9. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer. Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041 [TBL] [Abstract][Full Text] [Related]
10. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB; J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181 [TBL] [Abstract][Full Text] [Related]
11. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
12. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169 [TBL] [Abstract][Full Text] [Related]
13. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer. van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720 [TBL] [Abstract][Full Text] [Related]
14. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. Reiberger T; Ferlitsch A; Payer BA; Mandorfer M; Heinisch BB; Hayden H; Lammert F; Trauner M; Peck-Radosavljevic M; Vogelsang H; J Hepatol; 2013 May; 58(5):911-21. PubMed ID: 23262249 [TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395 [TBL] [Abstract][Full Text] [Related]
16. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142 [TBL] [Abstract][Full Text] [Related]
17. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992 [TBL] [Abstract][Full Text] [Related]
18. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A Oncology; 2005; 69(4):348-53. PubMed ID: 16293974 [TBL] [Abstract][Full Text] [Related]
19. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie. du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296 [TBL] [Abstract][Full Text] [Related]
20. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]